-65.1%
QBTS vs MRNA
+945.0%
-1,010.1%
-68.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.1% | +13.1% | -13.0% | -0.7% |
| 7D | -11.8% | +20.6% | -32.5% | -12.9% |
| 30D | -33.6% | +27.1% | -60.8% | -34.7% |
| 3M | -52.5% | +353.4% | -405.8% | -59.6% |
| 6M | -50.4% | +446.3% | -496.6% | -62.1% |
| YTD | -60.3% | +776.2% | -836.5% | -77.0% |
| 1Y | -65.1% | +987.9% | -1,053.0% | -81.8% |
| All | -65.1% | +945.0% | -1,010.1% | -81.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling